MS Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci U S A.
1986;838370- 8374Link to Article
et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolemia. Atherosclerosis.
1996;119203- 213Link to Article
KL Mechanisms of triglyceride-lowering effect of HMG-CoA reductase inhibitor in a hypertriglyceridemic model, the Zucker obese rat. J Lipid Res. 1992;331- 7
et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol.
1995;15678- 682Link to Article
et al. A brief review paper of the efficacy and safety of atorvastatin in early clinical trials. Atherosclerosis.
1997;13117- 23Link to Article
et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA.
1996;275128- 133Link to Article
et al. Expanded clinical evaluation of lovastatin (EXCEL) study results, IV: additional perspectives on the tolerability of lovastatin. Am J Med.
25S- 30SLink to Article
J Extended clinical safety profile of lovastatin. Am J Cardiol.
1990;6611B- 15BLink to Article
et al. Expanded clinical evaluation of lovastatin (EXCEL) study results, I: efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med.
1991;15143- 49Link to Article
et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: 2-year efficacy and safety follow-up. Am J Cardiol.
1994;74667- 673Link to Article
Lovastatin Study Groups I-IV, Lovastatin 5-year safety and efficacy study. Arch Intern Med.
1993;1531079- 1087Link to Article
et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia, II: once-daily versus twice-daily dosing. Atherosclerosis.
1990;85219- 227Link to Article
et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia, I: a dose-response study. Atherosclerosis.
1990;8581- 89Link to Article
et al. The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia. J Intern Med.
1990;228261- 266Link to Article
et al. Efficacy and safety of pravastatin once daily in primary moderate hypercholesterolemia: the Israeli experience. Isr J Med Sci. 1993;2272- 277
Pravastatin Multicenter Study Group II, Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Arch Intern Med.
1993;1531321- 1329Link to Article
A Treatment of primary hypercholesterolaemia with pravastatin: efficacy and safety over 3 years. Med J Aust. 1992;157584- 589
LA Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. Clin Cardiol.
1993;16317- 322Link to Article
et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med.
1996;1562085- 2092Link to Article
et al. Efficacy and safety of simvastatin (alone or in association with colestyramine): a 1-year study in 66 patients with type II hyperlipoproteinaemia. Eur Heart J. 1990;11149- 155
et al. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J.
1994;15255- 269Link to Article
A Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Arch Intern Med.
1994;154441- 449Link to Article
AG Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolaemia. Atherosclerosis.
S21- S28Link to Article
ME Long-term safety and efficacy profile of simvastatin. Am J Cardiol.
1991;681127- 1131Link to Article
et al. Treatment of primary hypercholesterolaemia: short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study. J Intern Med.
1993;23477- 82Link to Article
The Simvastatin Pravastatin Study Group, Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol.
1993;711408- 1414Link to Article
TK Safety profile of fluvastatin. Br J Clin Pract Symp Suppl. 1996;77A20- 23
MH Fluvastatin Long-term Extension Trial (FLUENT): summary of efficacy and safety. Am J Med.
41S- 44SLink to Article
NE Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother. 1995;29743- 759
J Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J.
1995;165- 13Link to Article
JA The clinical efficacy and safety of lovastatin and MK-733: an overview. Eur Heart J.
93- 96Link to Article
et al. The efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis.
1997;130191- 197Link to Article
et al. Atorvastatin, a new HMG-CoA reductase inhibitor as monotherapy and combined with colestipol. J Cardiovasc Pharmacol Ther. 1996;1117- 122
et al. A multicenter, double-blind, 1-year study comparing the safety and efficacy of once-daily atorvastatin with that of simvastatin in patients with hypercholesterolemia. Am J Cardiol.
1997;8039- 44Link to Article
et al. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-blind study. Clin Ther.
1996;18853- 863Link to Article
et al. Comparison of 1-year efficacy and safety of atorvastatin-versus-lovastatin in primary hypercholesterolemia: Atorvastatin Study Group I. Am J Cardiol.
1997;791475- 1481Link to Article
et al. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate. Arterioscler Thromb Vasc Biol.
1997;171793- 1799Link to Article
DM An evaluation of estrogen and atorvasatin, a new HMGRI, in hypercholesterolemic postmenopausal women. Presented at the 66th Congress of the European Atherosclerosis Society July 13, 1996 Florence, Italy
et al. Atorvastatin causes a dose-dependent reduction in LDL-C and triglycerides. Presented at the 66th Congress of the European Atherosclerosis Society July 13, 1996 Florence, Italy
et al. Comparison of atorvastatin, a new HMG-CoA reductase inhibitor, with pravastatin and simvastatin. Atherosclerosis.
314Link to Article
KM Atorvastatin and simvastatin reduce elevated cholesterol in non-insulin dependent diabetes. Diab Nutr Metab. 1996;974- 80
B Influence of 2 hydroxymethylgluteryl coenzyme-A reductase inhibitors on postprandial lipoprotein and apo B-48 metabolism. Presented at the 66th Congress of the European Atherosclerosis Society July 13, 1996 Florence, Italy
D A 12-week study comparing atorvastatin with niacin patients with hypertriglyceridemia with or without hypercholesterolemia. Presented at the 66th Congress of the European Atherosclerosis Society July 13, 1996 Florence, Italy
L Atorvastatin, a new HMG-CoA reductase inhibitor is safe and effective in NIDDM patients with hyperlipidemia. Presented at the 66th Congress of the European Atherosclerosis Society July 13, 1996 Florence, Italy
D Atorvasatin monotherapy and combination therapy in the treatment of severe hypercholesterolemia. Atherosclerosis.
S20Link to Article
D A 1-year treat-to-target study of atorvastatin vs pravastatin in risk-stratified hypercholesterolemic patients. Presented at the 66th Congress of the European Atheroslcerosis Society July 13,1996 Florence, Italy
J Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolaemia. Arterioscler Thromb Vasc Biol.
1997;171527- 1531Link to Article
DM Changes in hemorheology and atherothrombotic parameters by improving serum lipids in atorvastatin. Presented at the 66th Congress of the European Atherosclerosis Society July 13,1996 Florence, Italy
GR Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J Lipid Res. 1997;382071- 2078
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA.
1993;2693015- 3023Link to Article
National Diabetes Data Group, Classification and diagnosis of diabetes and other areas of glucose intolerance. Diabetes. 1979;28139- 157
Food and Drug Administration, Dept of Health and Human Services, COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms. 4th ed. Washington, DC Food and Drug Administration, Dept of Health and Human Services1993;
R High elevations of creatine phosphokinase in hypothyroidism: an isoenzyme analysis. JAMA.
1977;238325- 326Link to Article
JC The genotoxicity profile of atorvastatin, a new drug in the treatment of hypercholesterolemia. Mutat Res.
1995;34395- 107Link to Article
Not Available, 1996 Physicians' Desk Reference. 50th ed. Montvale, NJ Medical Economics Co1996;765- 7691699- 17031775- 17792267- 2269
Parke-Davis Pharmaceutical Research Division, Warner-Lambert Co, Lipitor [package insert]. Ann Arbor, Mich. Parke-Davis Pharmaceutical Research Division Warner-Lambert Co1997;
A Acute cholestatic hepatitis during simvastatin administration. Recenti Prog Med. 1991;82233- 235
GE Clinical experience with lovastatin. Am J Cardiol.
1990;6523F- 26FLink to Article
H Drug-associated asymptomatic elevations of transaminase in drug safety assessments. Pharmacotherapy. 1995;1523- 25
TP Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA.
1990;26471- 75Link to Article